Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1111 to 1125 of 1308 results for social care

  1. The NxStage System One NX1000‑1 home haemodialysis device for renal replacement therapy in chronic kidney disease (MIB12)

    NICE has developed a medtech innovation briefing (MIB) on The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease .

    Medtech innovation briefing
    Published
    19 November 2014

  2. Durvalumab with chemotherapy for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations [ID3751]

    Discontinued Reference number: GID-TA10616

    Technology appraisal guidance
    Discontinued

  3. Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]

    Discontinued Reference number: GID-TA10334

    Technology appraisal guidance
    Discontinued

  4. Guadecitabine for untreated acute myeloid leukaemia [ID1411]

    Discontinued Reference number: GID-TA10325

    Technology appraisal guidance
    Discontinued

  5. Ibrutinib for untreated mantle cell lymphoma [ID1221]

    Discontinued Reference number: GID-TA10185

    Technology appraisal guidance
    Discontinued

  6. Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

    Discontinued Reference number: GID-TA10597

    Technology appraisal guidance
    Discontinued

  7. Canakinumab with pembrolizumab and chemotherapy for untreated advanced non-small cell lung cancer with no EGFR or ALK mutations [ID3977]

    Discontinued Reference number: GID-TA10857

    Technology appraisal guidance
    Discontinued

  8. Plitidepsin with dexamethasone for treating multiple myeloma after 3 previous therapies including bortezomib and lenalidomide [ID1081]

    Discontinued Reference number: GID-TA10171

    Technology appraisal guidance
    Discontinued

  9. Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]

    Discontinued Reference number: GID-TA10427

    Technology appraisal guidance
    Discontinued

  10. Benralizumab for previously treated severe nasal polyps [ID1659]

    Discontinued Reference number: GID-TA10818

    Technology appraisal guidance
    Discontinued

  11. Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

    Discontinued Reference number: GID-TA10763

    Technology appraisal guidance
    Discontinued

  12. Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma [ID997]

    Discontinued Reference number: GID-TA10382

    Technology appraisal guidance
    Discontinued

  13. Durvalumab with tremelimumab for untreated EGFR- and ALK-negative locally advanced and metastatic non-small-cell lung cancer [ID1538]

    Discontinued Reference number: GID-TA10422

    Technology appraisal guidance
    Discontinued

  14. Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

    Discontinued Reference number: GID-TA10803

    Technology appraisal guidance
    Discontinued

  15. Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]

    Discontinued Reference number: GID-TA10380

    Technology appraisal guidance
    Discontinued